Discover your next big idea for life sciences at PACK EXPO Las Vegas
Experience a breakthrough in life sciences packaging—explore solutions from 2,300 suppliers spanning all industries, all in one place this September

Novo Nordisk, Valo Health Using AI to Develop Treatments

The two companies will apply Valo’s Opal Computational Platform™ and real-world patient dataset to enable the discovery and creation of novel cardiometabolic drug programs.

Novo Nordisk Ai

Novo Nordisk and Valo Health have entered into an agreement to discover and develop novel treatments for cardiometabolic diseases based on Valo’s large human dataset and computation powered by artificial intelligence (AI).

The collaboration between the two organizations will leverage the capabilities of Valo’s Opal Computational Platform™ including access to real-world patient data, AI-enabled small molecule discovery, and Biowire® human tissue modeling platform designed to speed up the discovery and development process.

Valo’s preclinical capabilities enable identification and validation of novel druggable targets, as well as the development of drug candidates against these targets, and can help predict compound safety and efficacy.

In addition to target discovery and validation as part of the collaboration, Novo Nordisk is licensing three preclinical drug discovery programs in cardiovascular diseases discovered and developed by Valo using the Opal Computational Platform™.

Under the terms of the agreement, Valo will receive an upfront payment and a potential near-term milestone payment, totaling $60 million dollars, and is eligible to receive milestone payments for up to 11 programs, totaling up to $2.7 billion, plus R&D funding and potential royalty payments. The partnership between Novo Nordisk and Valo will leverage key joint capabilities in human data and genetics with a stronghold in cardiometabolic diseases.

Valo’s Opal Computational Platform™ is an integrated, end-to-end drug discovery and development platform with a unified architecture founded upon high-quality, proprietary and differentiated human-centric data and purpose-built AI. Opal is designed to enable a fully integrated, efficient approach for targeting and advancing product candidates, from understanding the underlying disease through regulatory approval.


Fill out the form below to request more information about Novo Nordisk, Valo Health Using AI to Develop Treatments
Medical Device Innovations Report
Cutting-edge packaging technologies are transforming the medical device sector in PMMI’s “Innovation in Medical Device” report, featuring advanced materials, smart solutions, and evolving regulations. Editors share insights from nearly 300 PACK EXPO booth visits—each product deemed new and truly innovative—alongside video demonstrations of the equipment and materials on display.
Learn More
Medical Device Innovations Report
Pharmaceutical Innovations Report
Discover the latest breakthrough packaging technologies shaping the pharmaceutical sector. This report dives into cutting-edge innovations, from smart containers that enhance patient safety to eco-friendly materials poised to transform the industry’s sustainability practices. All from PACK EXPO. Learn how forward-thinking strategies are driving efficiency and redefining what’s possible in pharma packaging.
Learn More
Pharmaceutical Innovations Report